Dr. Ehlers cautioned that the changes must be considered in the context of the overall improvements in angiographic appearance. For example, subtle hypofluorescence associated with ischemia may be apparent more in the presence of significant leakage. As the leakage improves, the hypofluorescence may be less recognizable, but not necessarily “reperfused.”
He cautioned that this study was a preliminary analysis of a subset eyes and that the study had no control group. The complete 6-month dataset is expected to be available in early 2018.
The investigators expect to conduct additional analyses of the underlying diagnosis and treatment response and their implications related to the vascular dynamics and how they might be used to help in the understanding of the patient responses to anti-VEGF therapy. Fluid burden assessment with higher order quantitative OCT assessment will also be evaluated with quantitative ultra-widefield angiographic features, Dr. Ehlers said.